SCHEMBL6930406

SCHEMBL6930406

Cc1ccc(NC(=O)Nc2ccc(C(CC=O)C(=O)O)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.55
ALDH1A1 P00352 5/20 0.49
CASR P41180 1/20 0.47
NPC1 O15118 6/20 0.44
MAPT P10636 3/20 0.44
SLC6A3 Q01959 1/20 0.44
POLB P06746 2/20 0.44
PTPN7 P35236 1/20 0.43
RAB9A P51151 6/20 0.43
NMT1 P30419 1/20 0.42
IDO1 P14902 1/20 0.41
MEN1 O00255 2/20 0.41
TP53 P04637 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
GFER P55789 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6931854 0.88 CASP3 (0.54) SMN1; SMN2NPC1MAPTPOLBRAB9A
SCHEMBL1147878 0.88 POLB (0.50) SMN1; SMN2ALDH1A1POLBRAB9AMEN1
SCHEMBL6931406 0.87 MAOA (0.54) RAB9AMEN1KMT2A
SCHEMBL6931995 0.86 MEN1 (0.46) SMN1; SMN2NPC1MAPTSLC6A3POLB
SCHEMBL6931346 0.86 CNR1 (0.51) SMN1; SMN2ALDH1A1CASRNPC1MAPT
SCHEMBL6931563 0.85 RAB9A (0.59) SMN1; SMN2CASRNPC1MAPTPOLB
SCHEMBL6930408 0.79 GAA (0.54) SMN1; SMN2ALDH1A1NPC1MAPTPOLB
SCHEMBL6925981 0.78 CA12 (0.51) SMN1; SMN2ALDH1A1NPC1MAPTRAB9A
SCHEMBL27953192 0.75 LMNA (0.47) SMN1; SMN2ALDH1A1MEN1KMT2AHPGD
SCHEMBL20826432 0.74 L3MBTL1 (0.54) SMN1; SMN2ALDH1A1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US claimed
US-6541521-B1 Particularly gelatinase A, collagenase-3, and stromelysin-1 WARNER-LAMBERT COMPANY 2003-04-01 US claimed
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2002-10-31 US claimed
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US disclosed
US-6541521-B1 Particularly gelatinase A, collagenase-3, and stromelysin-1 WARNER-LAMBERT COMPANY 2003-04-01 US disclosed
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2002-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases MMP1, MMP8, MMP13 SMN1; SMN2 208/4885ALDH1A1 1135/4885CASR 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.